Navigation Links
AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
Date:4/15/2008

QUEBEC CITY, April 15 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported the completion of patient recruitment for the Company's first efficacy trial of its Phase 3 program in benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate, with its flagship product candidate, cetrorelix. The study involves approximately 600 patients primarily in the United States and Canada, with additional sites in Europe.

"We are very proud to have reached this important milestone. The Phase 3 program in BPH with cetrorelix is on track and we expect to provide results in the third quarter of 2009 as stated previously," commented Paul Blake, M.D., Senior Vice President and Chief Medical Officer of AEterna Zentaris.

This first efficacy study, titled "Cetrorelix pamoate intermittent IM dosage regimens in patients with symptomatic BPH: a 1-year placebo-controlled efficacy study and long-term safety assessment", will assess an intermittent dosage regimen of cetrorelix as a safe and tolerable treatment providing prolonged improvement in BPH-related signs and symptoms.

About the Phase 3 Program with Cetrorelix in BPH

The first multi-center efficacy study commenced first patient randomization in April 2007 and completion of patient recruitment was announced today. It is currently being conducted primarily in the United States and Canada, with additional sites in Europe and involves approximately 600 patients under the supervision of lead investigator, Herbert Lepor, MD, Professor at NY University School of Medicine, New York. Patients enter a 4-week run-in no-treatment observation period to confirm sever
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris Announces Changes to its Management Team
2. AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights
3. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
4. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
5. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
6. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
9. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
10. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
11. AEterna Zentaris Announces Outcome of Managements Strategic Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 /PRNewswire-iReach/ -- Tute Genomics, the ... announced an agreement with Lineagen, Inc., to ... NextStep Dx PLUS.  Lineagen, focused on ... disorders, currently offers FirstStep Dx PLUS, ... used by healthcare providers as a first-line ...
(Date:7/10/2014)... may help in the fight against terrorism with the ... of explosives with the use of light and special ... and Actuators B: Chemical , the researchers describe a ... concentrations as low as 6.3 ppm (parts per million). ... minutes. , "Traditionally explosives detection has involved looking for ...
(Date:7/10/2014)... fractional quantum Hall effect in bilayer graphene and shown ... by an electric field. , The fractional quantum ... thin sheets are exposed to large magnetic fields, is ... individual electrons behave as a single system. However, while ... many details of this collective behavior remain not well ...
(Date:7/10/2014)... University of Illinois at Urbana-Champaign provides new insights ... spin and heat at the nanoscale, and addresses ... data storage and information processing. , "Electrons ... In a typical charge current, electrons, spin-angular-momentum is ... David Cahill, a professor of materials science and ...
Breaking Biology Technology:Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Detecting trace amounts of explosives with light 2Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3University of Illinois study advances limits for ultrafast nano-devices 2
... created equal. Information lifecycle management, a fresh concept in ... and placed them into tiers associated with different costs ... from customer orders to pictures of your last fishing ... elses data. Each piece of data doesnt have the ...
... transfer and commercialization efforts are on the rise in ... of Wisconsin to intensify its efforts at technology transfer, ... Center for Advanced Technology & Innovation (CATI) ... industry technology transfer in the Madison area. We Energies ...
... Science faculty at the University of Wisconsin-Eau Claire ... opportunities to work on research relating to materials ... university to assist local industries. , ,UW-Eau Claires ... facilitate collaboration among science faculty across disciplines, promote ...
Cached Biology Technology:Save money while your data grows 2Madison Development Corp. and CATI form tech transfer partnership 2UW-Eau Claire creates Materials Science Center 2UW-Eau Claire creates Materials Science Center 3
(Date:7/11/2014)... kidney injury related to the use of hydroxyethyl starch ... molecules, according to a report in Anesthesia & ... Society (IARS). , The "total mass of HES molecules" ... renal proximal tubule cells (PTCs), concludes the laboratory study ... Wrzburg, Austria. Other factorssuch as differences in the ...
(Date:7/11/2014)... addition to the hippocampus, the marginal division of ... memory. What is the impact degree of substance ... and memory function? Yan Yu and his team, ... found, using immunofluorescence staining, that substance P receptor, ... and striatal marginal division of normal rats. Unilateral ...
(Date:7/11/2014)... Evidence exists that cannabinoid receptor type 1 ... Ca2+ influx, and reduce neurotransmitter release. However, ... 1 can increase extracellular Ca2+ influx and ... his team, Tongji Hospital Affiliated to Tongji ... Technology, China used whole cell voltage-clamp and ...
Breaking Biology News(10 mins):In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... by scientists at The University of Texas Medical School ... vascular smooth-muscle cells in people who suffer from hereditary ... warning in the prime of their lives. Thoracic ... dissections, is the 15th leading cause of death in ...
... appealed for more information on the worlds biodiversity to ... to understand the impact of climate change on the ... by the Biotechnology and Biological Sciences Research Council (BBSRC), ... and computer scientists at the University of Cardiff, has ...
... Researchers at Childrens Hospital of Pittsburgh of UPMC are participating ... effectiveness of oral insulin in preventing or delaying the onset ... disease. The researchers want to determine if one insulin ... type 1 diabetes in relatives of people who are found ...
Cached Biology News:Life-threatening gene defect located by UT-Houston researchers 2Life-threatening gene defect located by UT-Houston researchers 3Life-threatening gene defect located by UT-Houston researchers 4How global is the Global Biodiversity Information Facility? 2Children's Hospital studying drug with the potential to prevent/delay onset of type 1 diabetes 2
...
For mRNA Differential Display with three one-base anchored oligo-dT primers and rationally designed arbitrary 13mers. These kits feature the latest generation of isotopic mRNA Differential Display t...
NATIVE, ENZYME PORCINE TRYPSIN...
G-Protein Coupled Receptor Assay, For 500 assays. SPA. Category: Drug Screening & Cellular Assays, Assays ....
Biology Products: